About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Depressed, Anxious Breast Cancer Women Likely to Use Opioids & Die Early

by Ramya Rachamanti on August 27, 2019 at 5:00 PM
Font : A-A+

Depressed, Anxious Breast Cancer Women Likely to Use Opioids & Die Early

Breast cancer women with anxiety, depression or other mental health issues are more likely to use opioids and die early, according to a new study led by the University of Virginia School of Medicine.

"The complex relationship among breast cancer, mental health problems, and the use of opioids is not well understood and the results of this study provide clinicians the evidence they need to make optimal patient treatment related decisions," said lead researcher Rajesh Balkrishnan, PhD, of the Department of Public Health Sciences and the UVA Cancer Center. "Our findings suggest that patients with breast cancer with mental health conditions have higher opioid use and reduced survival. These results highlight the need for health care providers to evaluate treatment goals and assess whether better concurrent management of breast cancer and mental health conditions is required."

Advertisement


Breast Cancer and Opioids

Breast cancer kills more than 40,000 people in the United States each year, and patients often suffer from anxiety and depression. Research suggests that about 40 percent of patients with breast cancer have some type of mental health diagnosis.
Advertisement

Balkrishnan and his team set out to shed light on the relationship among mental health, opioid use and breast cancer outcomes. To do that, they reviewed more than 10,000 breast cancer cases recorded in the national SEER cancer database, which contains detailed (but depersonalized) information on care provided to Medicare beneficiaries with cancer.

These cases consisted of women aged 65 years and older who were diagnosed with stage I, II or III breast cancer between Jan. 1, 2006, and Dec. 31, 2012. All received adjuvant endocrine therapy as treatment.

The researchers sorted the cases into two groups: women with mental health diagnoses and those without. They found that those with mental health diagnoses had higher opioid use and lower survival rates.

"Opioid use is higher in the women with breast cancer who suffer from mental health comorbidities and remains a significant problem," the researchers write in a new paper outlining their findings. "In addition, mental health comorbidities also contribute to reduced survival in these women. A need exists for collaborative care in the management of mental health comorbidities in women with breast cancer, which could improve symptoms, adherence to treatment, and recovery from these mental conditions. Mental health treatments also are recommended to be offered in primary care, which not only would be convenient for patients but also would reduce the stigma associated with treatments for mental health comorbidities and improve the patient-provider relationship."

The researchers, including UVA palliative care expert Leslie Blackhall, MD, recommend that doctors and other care providers consider "complementary forms of treatment for pain," such as physical therapy, cognitive behavioral therapy, acupuncture, acupressure and massage.

Findings Published

The researchers have published their findings in the Journal of Oncology Practice. In addition to Balkrishnan and Blackhall, the study's authors were Raj Desai, of the University of Florida; Fabian Camacho of the UVA School of Medicine; Xi Tan of West Virginia University; and Virginia LeBaron, of the UVA School of Nursing.

The researchers noted potential limitations to their study such as a lack of information on the opioids used and a lack of details on the patients' pain assessments. They also suggest that mental health conditions such as depression may be underdiagnosed and that, as a result, the research may underestimate the percentage of patients with those conditions.

Tan disclosed potential conflicts of interest including owning stock in and receiving compensation from biopharmaceutical company Merck. Balkrishnan disclosed that he has done consulting or advising for Merck.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Anxiety Disorder Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Cannabis Drug Abuse Breast Cancer Facts Cancer Facts 

Recommended Reading
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical ......
Anxiety Disorder
Anxiety disorder involves excessive worry about actual circumstances, events or conflicts. Anyone ca...
Breast Biopsy
Breast biopsy involves removing a sample of breast tissue to determine whether it is cancerous or .....
Cannabis
Cannabis has a long history of medicinal, recreational, and industrial use and comes from a bushy pl...
Drug Abuse
The use of Drugs for reasons other than its prescribed recommendation, is known as Drug abuse or sub...
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...
Pagets disease of the breast
A detailed description of the Paget's disease of the breast, characteristic signs and symptoms, dete...
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of l...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use